SS-31 Spray50mg
SS-31 Spray Canada — Nasal Spray
Mitochondria-Targeted Tetrapeptide
SS-31 is a synthetic aromatic-cationic tetrapeptide that associates with the inner mitochondrial membrane. It is supplied in a spray presentation for laboratory research and is studied under controlled experimental conditions.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
SS-31 is a synthetic aromatic-cationic tetrapeptide that associates with the inner mitochondrial membrane. It is supplied in a spray presentation for laboratory research and is studied under controlled experimental conditions.
In scientific literature, SS-31 is examined in models of mitochondrial dysfunction, with published work addressing cardiolipin interaction, mitochondrial protein organization, oxidative stress signaling, and inflammasome-associated pathways in cell and rodent systems.
SS-31, also designated elamipretide, is characterised in the literature as a mitochondria-targeting peptide that accumulates at the inner mitochondrial membrane through interaction with cardiolipin. Cross-linking mass spectrometry work has mapped an interaction landscape spanning multiple inner-membrane proteins, and a genome-wide CRISPR screen has reported phospholipid scramblase 3 as a biological target associated with its mitoprotective activity. Review material groups it with compounds investigated for effects on mitochondrial bioenergetics and reactive oxygen species handling.
Research endpoints evaluated in preclinical systems include mitochondrial respiration and membrane integrity, ferroptosis markers in hypoxia/reoxygenation cardiomyocyte models, Drp1-associated fission and NLRP3 inflammasome activation, mtDNA-cGAS-STING signaling and mitophagy in aged rodents, macrophage polarization in hepatic ischemia-reperfusion models, autophagy-related protein expression in stimulated hepatocyte lines, Nrf2-dependent inflammasome signaling in pulmonary fibrosis models, and renal injury models. Behavioural and cognitive endpoints have also been recorded in rodent neuroinflammation and sepsis-associated encephalopathy studies.
SS-31 belongs to the Szeto-Schiller series of aromatic-cationic peptides developed during investigation of cell-permeable compounds that concentrate in mitochondria. The published record documents its use as a mitochondrial-targeted antioxidant across a broad range of injury models, though the detailed early development chronology is not covered by the references available here.
The research record expanded substantially through rodent and cell-culture work on kidney, liver, lung, heart and brain injury models. More recent publications have shifted toward target identification, including proteomic mapping of its mitochondrial protein interactions and a CRISPR-based screen identifying phospholipid scramblase 3. The compound also appears in review literature surveying peptides discussed in musculoskeletal and performance contexts, where its regulatory and evidentiary status is assessed.
Laboratory investigations into SS-31 are organised around mitochondrial targeting and bioenergetic research. Frameworks include cardiolipin and inner-membrane protein interaction studies, oxidative stress and ferroptosis models in cardiomyocytes, inflammasome and innate immune signaling models in macrophages and hepatocytes, mitophagy and mtDNA release pathways in aged rodents, and organ injury models covering kidney, liver and lung tissue.
3 of the 5 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Chavez 2020, Zhao 2019, Du 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on ferroptosis, hypoxia or reoxygenation. This heading marks where SS-31 Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on nlrp3, inflammasome or innate. This heading marks where SS-31 Spray is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Ji 2024. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Zhu 2022. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 6 primary papers published between 2019 and 2024 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
SS-31 Spray is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for SS-31 Spray, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
SS-31 Spray is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under mitochondrial membrane and cardiolipin interaction studies, ferroptosis models in hypoxia/reoxygenation cardiomyocytes and NLRP3 inflammasome and innate immune signaling research.
The 6 papers cited on this page, published between 2019 and 2024 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for SS-31 Spray is per lot, not per product. The current 50mg lot SS31-CA-26F-50 returned 99.768% purity, 50.86 mg measured, 101.7% of the labelled 50 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the vial matches the code on the certificate for SS-31 Spray. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy SS-31 Spray in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
SS-31 Spray ships as a prepared solution rather than as lyophilized powder, so it is already past the point at which a powder would be reconstituted. That shortens handling but tightens storage: a compound in solution is less stable than the same compound dry, and refrigeration from arrival onward is the relevant control.
The stability window for a solution is shorter than the shelf life of a sealed lyophilized vial of the same compound. Records for laboratory work in this format should note the date the unit was opened, not only the date it was received.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of SS-31 in the spray presentation. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the compound as supplied. Any laboratory materials required for handling, dilution, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31
PubMedElamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
PubMedSS-31 inhibits mtDNA-cGAS-STING signaling to improve POCD by activating mitophagy in aged mice
PubMedApplication research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
